List of Procysbi drug patents

Procysbi is owned by Horizon Pharma Usa.

Procysbi contains Cysteamine Bitartrate.

Procysbi has a total of 17 drug patents out of which 0 drug patents have expired.

Procysbi was authorised for market use on 14 February, 2020.

Procysbi is available in granule, delayed release;oral dosage forms.

Procysbi can be used as management of nephropathic cystinosis by administering a total daily dose in two divided doses.

The generics of Procysbi are possible to be released after 16 August, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925157 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9198882 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9192590 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9925156 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9925158 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9192590

(Pediatric)

HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9198882

(Pediatric)

HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US8026284 HORIZON PHARMA USA Enterically coated cystamine, cysteamine and derivatives thereof
Sep, 2027

(4 years from now)

US8026284

(Pediatric)

HORIZON PHARMA USA Enterically coated cystamine, cysteamine and derivatives thereof
Mar, 2028

(5 years from now)

US9233077 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9173851 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9233077

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US10328037 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10548859 HORIZON PHARMA USA Methods for storing Cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10905662 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10143665 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 22, 2024
Pediatric Exclusivity (PED) Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 14 February, 2020

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's patent expiration?
More Information on Dosage

Procysbi is owned by Horizon.

Procysbi contains Cysteamine Bitartrate.

Procysbi has a total of 24 drug patents out of which 0 drug patents have expired.

Procysbi was authorised for market use on 30 April, 2013.

Procysbi is available in capsule, delayed release;oral dosage forms.

Procysbi can be used as management of nephropathic cystinosis by administering a total daily dose in two divided doses.

The generics of Procysbi are possible to be released after 16 February, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9925158 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9925157 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9925156 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192590 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9198882 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9925158

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9925156

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9925157

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9198882

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9192590

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US8026284 HORIZON Enterically coated cystamine, cysteamine and derivatives thereof
Sep, 2027

(4 years from now)

US8026284

(Pediatric)

HORIZON Enterically coated cystamine, cysteamine and derivatives thereof
Mar, 2028

(5 years from now)

US9233077 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9173851 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9233077

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US10905662 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10548859 HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10328037 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10143665 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10905662

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

US10548859

(Pediatric)

HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

US10328037

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

US10143665

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 22, 2024
Pediatric Exclusivity (PED) Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in